Bionano (BNGO) COO Mark Oldakowski Receives 15,000-Share Option Award

What Happened

• Mark Oldakowski, Chief Operating Officer of Bionano Genomics (BNGO), received a derivative award reported as 15,000 shares on Aug 3, 2026. The award is reported at $0.00 (no cash paid at grant) and is filed on Form 4 (transaction code A = Award/Grant).

Key Details

• Transaction date: 2026-08-03; Form filed: 2026-08-05.
• Transaction type: A (award/grant) reported as a derivative (option/award) for 15,000 shares at $0.00.
• Vesting: Footnote indicates the award vests 50% on each of the first and second anniversaries of the vesting commencement date, subject to continued service under the 2018 Plan.
• Shares owned after transaction: Not specified in the provided filing.
• Filing note: This Form 4 replaces an erroneously filed Form 3 (per footnote); the replacement was filed two days after the transaction.

Context

• This is a grant of a derivative equity award to an executive — common as part of compensation and retention. Because no shares were sold or bought on the open market, this grant alone is not a direct buy/sell signal for immediate insider sentiment. The vesting schedule means the economic interest is tied to continued service over the next two years.